Market News

Theratechnologies Nosedives on Pausing Phase 1 Trial

Shares of biopharmaceutical company Theratechnologies (NASDAQ:THTX) are tanking today after it paused patient enrolment in the Phase 1 trial of its lead investigational candidate TH1902 for the treatment of sortilin-expressing cancers.

THTX now plans to submit an amended protocol to the U.S. Food and Drug Administration (FDA) for approval.

The move comes after observed efficacy results were not strong enough to continue enrolments and did not outweigh the observed adverse events in the trial.

Analysts, in the meantime, have a Moderate Buy consensus rating on the stock alongside an average price target of $7.50.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More